GLP-1 options continue to expand, and a new pill has just been FDA-approved. Eli Lilly’s Foundayo (orforglipron) is a once-daily oral medication for weight loss, adding to a growing category of treatments. Unlike injectable GLP-1 medications, Foundayo is taken as a tablet, offering an alternative for patients who are needle-averse or looking to move away from weekly injections.
What Makes It Unique
While oral GLP-1 medications already exist, Foundayo introduces a more flexible dosing approach. It can be taken once daily, with or without food, and without the strict timing requirements associated with earlier oral versions.
“Unlike the current oral version of semaglutide, orforglipron doesn’t have to be taken on an empty stomach, which could make it easier to fit into daily routines,” says Eduardo Grunvald, MD, a San Diego–based obesity specialist.
That flexibility may help simplify treatment for patients managing busy schedules or multiple medications, and may also help support long-term use once weight loss goals are reached.
What GLP-1 Users Should Know
If you’re already on a GLP-1, the biggest difference here is convenience. Foundayo can be taken with or without food, so there’s no timing around meals or waiting periods like earlier oral options. It also offers an oral alternative within the category, giving patients another way to take a GLP-1 without injections.
In clinical trials, patients taking the highest dose of orforglipron lost an average of 12.4 percent of their body weight over 72 weeks, or about 27 pounds. Even when accounting for all participants, average weight loss remained around 11 percent. That’s lower than the roughly 20 percent weight loss seen with tirzepatide in separate trials, though the two have not been studied head-to-head.
Side effects appear consistent with other GLP-1 medications, including nausea, constipation, diarrhea and general stomach discomfort, especially in the early weeks. The same guidance applies: stay hydrated, pay attention to how your body responds and don’t ignore symptoms that feel severe or persistent. There are also the same bigger-picture considerations, including avoiding use in patients with certain thyroid cancers or MEN 2, so this is something to review carefully with your doctor, especially if you’re managing other medications or underlying conditions.
